专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07320871B2 Human prostaglandin FP receptor variants and methods of using same 有权
标题翻译：人类前列腺素FP受体变体及其使用方法
公开(公告)号：US07320871B2
公开(公告)日：2008-01-22
申请号：US10620289
申请日：2003-07-14
申请人： Yanbin Liang , David F. Woodward
发明人： Yanbin Liang , David F. Woodward
IPC分类号： C07K14/705 , G01N33/566
CPC分类号： G01N33/88 , C07K14/72 , G01N2500/04
摘要： The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25. The invention also provides an isolated polypeptide containing an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 14 and an amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25, or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, or 12. The invention also provides a method for identifying a compound that modulates a FP receptor variant by contacting an isolated FP receptor variant or a FP receptor variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a FP receptor variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the FP receptor variant.
摘要翻译：本发明提供了含有SEQ ID NO：17,18,19,20,21,22,23,24或25的氨基酸序列的分离的多肽。本发明还提供了一种分离的多肽，其含有至少具有至少与SEQ ID NO：14的50％氨基酸同一性和SEQ ID NO：17,18,19,20,21,22,23,24或25的氨基酸序列或其保守变体。本发明还提供了含有SEQ ID NO：2,4,6,8,10或12的氨基酸序列的分离的多肽。本发明还提供了一种鉴定通过使分离的 FP受体变体或在具有化合物的遗传工程化细胞中过表达的FP受体变体，并确定与FP受体变体的调节相关的指标水平，其中与对照相比，指标水平的改变水平表示该化合物是调节FP受体变体的化合物。

2. 发明授权

US07612082B2 Prostaglandin EP4 antagonists 有权
标题翻译：前列腺素EP4拮抗剂
公开(公告)号：US07612082B2
公开(公告)日：2009-11-03
申请号：US10976442
申请日：2004-10-28
申请人： Larry A. Wheeler , Michael E. Garst , Yanbin Liang , David F. Woodward , Achim H.-P. Krauss , Robert M. Burk , Yariv Donde , Mark Holoboski , David W. Old , June Chen
发明人： Larry A. Wheeler , Michael E. Garst , Yanbin Liang , David F. Woodward , Achim H.-P. Krauss , Robert M. Burk , Yariv Donde , Mark Holoboski , David W. Old , June Chen
IPC分类号： A61K43/42
CPC分类号： A61K31/473 , Y10S514/913
摘要： Disclosed herein are methods and compositions related to compound 1 or compound 2 or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP4 receptor, or are prostaglandin EP4 antagonists.
摘要翻译：本文公开了与作为前列腺素EP4受体的拮抗剂或前列腺素EP4拮抗剂的化合物1或化合物2或其药学上可接受的盐或其前药相关的方法和组合物。

3. 发明授权

US07198928B2 Human COX-1 alternatively spliced variants and methods of using same 有权
标题翻译：人类COX-1可变剪接变体及其使用方法
公开(公告)号：US07198928B2
公开(公告)日：2007-04-03
申请号：US10663377
申请日：2003-09-15
申请人： Yanbin Liang , David F. Woodward
发明人： Yanbin Liang , David F. Woodward
IPC分类号： C12N9/02 , C12N1/20 , C12N15/70 , C12P21/06 , C07H21/04
CPC分类号： C12N9/0083
摘要： The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22 or 24. The invention also provides an isolated polypeptide containing a) an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 10, and b) an amino acid sequence selected from SEQ ID NOS: 14, 16, 18, 20, 22, or 24; or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8. The invention also provides a method for identifying a compound that modulates a COX-1 variant by contacting an isolated COX-1 variant or a COX-1 variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a COX-1 variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the COX-1 variant.
摘要翻译：本发明提供了含有SEQ ID NO：14,16,18,20,22或24的氨基酸序列的分离的多肽。本发明还提供了分离的多肽，其含有a）具有至少50％氨基酸同一性的氨基酸序列具有SEQ ID NO：10，和b）选自SEQ ID NO：14,16,18,20,22或24的氨基酸序列; 或其保守变体。本发明还提供了含有SEQ ID NO：2,4,6或8的氨基酸序列的分离的多肽。本发明还提供了通过使分离的COX-1接触来鉴定调节COX-1变体的化合物的方法变体或在具有化合物的遗传工程细胞中过表达的COX-1变体，并确定与COX-1变体的调节相关的指标水平，其中与对照相比，指标水平的变化水平表示该化合物是调节COX-1变体的化合物。

4. 发明申请

US20050084931A1 Human prostaglandin DP receptor variants and methods of using same 审中-公开
标题翻译：人前列腺素DP受体变体及其使用方法
公开(公告)号：US20050084931A1
公开(公告)日：2005-04-21
申请号：US10689861
申请日：2003-10-20
申请人： Yanbin Liang , David Woodward
发明人： Yanbin Liang , David Woodward
IPC分类号： C07H21/04 , C07K14/72 , C07K14/705
CPC分类号： C07H21/04 , C07K14/72
摘要： The present invention relates to a nucleic acid molecule encoding a novel, alternatively spliced DP receptor variant. A variant DP polypeptide and screening methods based on such a polypeptide also are provided.
摘要翻译：本发明涉及编码新的，可选择性剪接的DP受体变体的核酸分子。还提供了变体DP多肽和基于这种多肽的筛选方法。

5. 发明申请

US20060105346A1 Human prostaglandin FP receptor variants and methods of using same 有权
标题翻译：人类前列腺素FP受体变体及其使用方法
公开(公告)号：US20060105346A1
公开(公告)日：2006-05-18
申请号：US10620289
申请日：2003-07-14
申请人： Yanbin Liang , David Woodward
发明人： Yanbin Liang , David Woodward
IPC分类号： G01N33/00 , C12Q1/68 , C07H21/04 , C07K14/705 , C07K16/28
CPC分类号： G01N33/88 , C07K14/72 , G01N2500/04
摘要： The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25. The invention also provides an isolated polypeptide containing an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 14 and an amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25, or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, or 12. The invention also provides a method for identifying a compound that modulates a FP receptor variant by contacting an isolated FP receptor variant or a FP receptor variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a FP receptor variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the FP receptor variant.
摘要翻译：本发明提供了含有SEQ ID NO：17,18,19,20,21,22,23,24或25的氨基酸序列的分离的多肽。本发明还提供了一种分离的多肽，其含有至少具有至少与SEQ ID NO：14的50％氨基酸同一性和SEQ ID NO：17,18,19,20,21,22,23,24或25的氨基酸序列或其保守变体。本发明还提供了含有SEQ ID NO：2,4,6,8,10或12的氨基酸序列的分离的多肽。本发明还提供了一种鉴定通过使分离的 FP受体变体或在具有化合物的遗传工程化细胞中过表达的FP受体变体，并确定与FP受体变体的调节相关的指标水平，其中与对照相比，指标水平的改变水平表示该化合物是调节FP受体变体的化合物。

6. 发明申请

US20050233429A1 Human COX-1 alternatively spliced variants and methods of using same 有权
标题翻译：人类COX-1可变剪接变体及其使用方法
公开(公告)号：US20050233429A1
公开(公告)日：2005-10-20
申请号：US10663377
申请日：2003-09-15
申请人： Yanbin Liang , David Woodward
发明人： Yanbin Liang , David Woodward
IPC分类号： C07H21/04 , C07K16/40 , C12N20060101 , C12N9/02
CPC分类号： C12N9/0083
摘要： The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22 or 24. The invention also provides an isolated polypeptide containing a) an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 10, and b) an amino acid sequence selected from SEQ ID NOS: 14, 16, 18, 20, 22, or 24; or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8. The invention also provides a method for identifying a compound that modulates a COX-1 variant by contacting an isolated COX-1 variant or a COX-1 variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a COX-1 variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the COX-1 variant.
摘要翻译：本发明提供了含有SEQ ID NO：14,16,18,20,22或24的氨基酸序列的分离的多肽。本发明还提供了分离的多肽，其含有a）具有至少50％氨基酸同一性的氨基酸序列具有SEQ ID NO：10，和b）选自SEQ ID NO：14,16,18,20,22或24的氨基酸序列; 或其保守变体。本发明还提供了含有SEQ ID NO：2,4,6或8的氨基酸序列的分离的多肽。本发明还提供了通过使分离的COX-1接触来鉴定调节COX-1变体的化合物的方法变体或在具有化合物的遗传工程细胞中过表达的COX-1变体，并确定与COX-1变体的调节相关的指标水平，其中与对照相比，指标水平的改变水平表示该化合物是调节COX-1变体的化合物。

7. 发明申请

US20050084929A1 Human prostaglandin EP4 receptor variants and methods of using same 审中-公开
标题翻译：人前列腺素EP4受体变体及其使用方法
公开(公告)号：US20050084929A1
公开(公告)日：2005-04-21
申请号：US10688790
申请日：2003-10-17
申请人： Yanbin Liang , David Woodward
发明人： Yanbin Liang , David Woodward
IPC分类号： C07H21/04 , C07K14/72 , C07K14/71
CPC分类号： C07K14/72 , C07H21/04
摘要： The present invention provides alternatively spliced EP4 receptor variants, as well as related nucleic acid molecules and screening methods.
摘要翻译：本发明提供了可选择的剪接的EP4受体变体，以及相关的核酸分子和筛选方法。

8. 发明申请

US20060094742A1 Prostaglandin EP4 antagonists 有权
标题翻译：前列腺素EP4拮抗剂
公开(公告)号：US20060094742A1
公开(公告)日：2006-05-04
申请号：US10976442
申请日：2004-10-28
申请人： Larry Wheeler , Michael Garst , Yanbin Liang , David Woodward , Achim Krauss , Robert Burk , Yariv Donde , Mark Holoboski , David Old , June Chen
发明人： Larry Wheeler , Michael Garst , Yanbin Liang , David Woodward , Achim Krauss , Robert Burk , Yariv Donde , Mark Holoboski , David Old , June Chen
IPC分类号： A61K31/473
CPC分类号： A61K31/473 , Y10S514/913
摘要： Disclosed herein are methods and compositions related to compound 1 or compound 2 or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP4 receptor, or are prostaglandin EP4 antagonists.
摘要翻译：本文公开的是与作为前列腺素EP4受体的拮抗剂的化合物1或化合物2或其药学上可接受的盐或前药相关的方法和组合物，或者是前列腺素EP 4 >拮抗剂。

9. 发明申请

US20050074847A1 Human prostaglandin EP1 receptor variants and methods of using same 审中-公开
标题翻译：人前列腺素EP1受体变体及其使用方法
公开(公告)号：US20050074847A1
公开(公告)日：2005-04-07
申请号：US10681029
申请日：2003-10-07
申请人： Yanbin Liang , David Woodward
发明人： Yanbin Liang , David Woodward
IPC分类号： C07K14/72 , C07K14/705 , C07H21/04
CPC分类号： C07K14/72
摘要： The present invention relates to nucleic acid molecules encoding novel, alternatively spliced EP1 receptor variants. Variant EP1 polypeptides and screening methods based on such polypeptides also are provided.
摘要翻译：本发明涉及编码新的，可选择剪接的EP1受体变体的核酸分子。还提供了变体EP1多肽和基于这些多肽的筛选方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式